Table 1.
Clinical and Demographical Characteristics
| N = 57 | |
|---|---|
| Age (years) | 57 (53–61) |
| Race, n (%) | |
| White | 51 (89) |
| African American | 4 (7) |
| Asian | 2 (4) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 11 (19) |
| Non-Hispanic or non-Latino | 46 (81) |
| BMI (kg/m2) | 26 (23–30) |
| Current smoking, n (%) | 19 (33) |
| Diabetes, n (%) | 9 (16) |
| Hypertension, n (%) | 16 (28) |
| Dyslipidemia, n (%) | 30 (53) |
| History of CVD event, n (%) | 4 (7) |
| Framingham risk score (%)a | 13 (9–20) |
| Blood pressure (mmHg) | |
| SBP | 122 (116–135) |
| DBP | 78 (72–83) |
| Lipid profile (mg/dL) | |
| Total cholesterol | 170 (148–199) |
| HDL cholesterol | 46 (41–54) |
| LDL cholesterol | 102 (80–118) |
| Triglycerides | 116 (72–170) |
| Fasting glucose (mg/dL) | 97 (89–105) |
| CD4+ T lymphocyte count (cells/ml) | 570 (404–765) |
| CD4+ T lymphocyte percentage (%) | 33 (26–40) |
| CD4+:CD8+ T lymphocyte ratio | 0.8 (0.5–1.4) |
| Time since HIV diagnosis (years) | 22 (12–26) |
| Time on ART (years) | 12 (7–18) |
| AIDS diagnosis, n (%) | 21 (37) |
| ART class, n (%) | |
| NRTI | 54 (95) |
| ABC | 12 (22) |
| TDF | 32 (59) |
| PI | 15 (26) |
| NNRTI | 19 (33) |
| INSTI | 15 (26) |
| Concomitant medication | |
| Statin, n (%) | 27 (47) |
| Angiotensin receptor blocker, n (%) | 9 (16) |
| Aspirin, n (%) | 24 (42) |
Data are expressed as median (IQR) unless otherwise indicated.
a
10-year risk of a cardiovascular event, https://www.framinghamheartstudy.org/risk-functions/cardiovascular-disease/10-year-risk.php#
ABC, abacavir; ART, antiretroviral therapy; CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL, high-density lipoprotein; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; LDL, low-density lipoprotein; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SBP, systolic blood pressure; TDF, tenofovir.